Key facts
- FuturedMe’s last known valuation is $15.4M (Jun 2019).
- It has raised $6.3M; the latest was Later Stage VC in Jan 2026.
- Notable investors include UntroD, FASTAR, Jafco.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for FuturedMe
- ·The full record, as it builds
Funding rounds
No funding rounds for FuturedMe are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About FuturedMe
Developer of a target protein degradation technology designed to develop and provide medicine for every disease. The company's technology has in-vitro and in-vivo technology and changes the undruggable target to a druggable target by breaking down proteins and providing personalized small molecule drug development, enabling businesses to provide medicine for every disease for a healthy life to patients.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2018
- Employees
- 8
- Website
- futuredme.com/
- Ownership
- Privately Held (backing)
FuturedMe doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FuturedMe shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FuturedMe in its N-PORT filings yet. We sweep new filings monthly.